Skip to content
Commercial Litigation Woods Lonergan LLP

212.684.2500

Copyright Litigation

GW Pharmaceuticals Submits Marketing Authorisation Application in ... - GlobeNewswire (press release)

December 29, 2017 - 7:00am

GW Pharmaceuticals Submits Marketing Authorisation Application in ...
GlobeNewswire (press release)
LONDON and CARLSBAD, Calif., Dec. 29, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary ...

and more »

GW Pharmaceuticals Submits Marketing Authorisation Application in ... - GlobeNewswire (press release)

December 29, 2017 - 7:00am

GW Pharmaceuticals Submits Marketing Authorisation Application in ...
GlobeNewswire (press release)
LONDON and CARLSBAD, Calif., Dec. 29, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary ...

and more »

GW Pharmaceuticals Submits Marketing Authorisation Application in ... - GlobeNewswire (press release)

December 29, 2017 - 7:00am

GW Pharmaceuticals Submits Marketing Authorisation Application in ...
GlobeNewswire (press release)
LONDON and CARLSBAD, Calif., Dec. 29, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary ...

and more »

GW Pharmaceuticals Submits Marketing Authorisation Application in ... - GlobeNewswire (press release)

December 29, 2017 - 7:00am

GW Pharmaceuticals Submits Marketing Authorisation Application in ...
GlobeNewswire (press release)
LONDON and CARLSBAD, Calif., Dec. 29, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary ...

and more »

GW Pharmaceuticals Submits Marketing Authorisation Application in Europe for Epidiolex® (cannabidiol) in the ... - GlobeNewswire (press release)

December 29, 2017 - 7:00am

GW Pharmaceuticals Submits Marketing Authorisation Application in Europe for Epidiolex® (cannabidiol) in the ...
GlobeNewswire (press release)
This news release contains forward-looking statements that reflect GW's current expectations regarding future events, including statements regarding financial performance, the timing of clinical trials, the timing and outcomes of regulatory or ...

and more »

GW Pharmaceuticals Submits Marketing Authorisation Application in Europe for Epidiolex® (cannabidiol) in the ... - GlobeNewswire (press release)

December 29, 2017 - 7:00am

GW Pharmaceuticals Submits Marketing Authorisation Application in Europe for Epidiolex® (cannabidiol) in the ...
GlobeNewswire (press release)
This news release contains forward-looking statements that reflect GW's current expectations regarding future events, including statements regarding financial performance, the timing of clinical trials, the timing and outcomes of regulatory or ...

and more »

GW Pharmaceuticals Submits Marketing Authorisation Application in Europe for Epidiolex® (cannabidiol) in the ... - GlobeNewswire (press release)

December 29, 2017 - 7:00am

GW Pharmaceuticals Submits Marketing Authorisation Application in Europe for Epidiolex® (cannabidiol) in the ...
GlobeNewswire (press release)
This news release contains forward-looking statements that reflect GW's current expectations regarding future events, including statements regarding financial performance, the timing of clinical trials, the timing and outcomes of regulatory or ...

and more »

GW Pharmaceuticals Submits Marketing Authorisation Application in Europe for Epidiolex® (cannabidiol) in the ... - GlobeNewswire (press release)

December 29, 2017 - 7:00am

GW Pharmaceuticals Submits Marketing Authorisation Application in Europe for Epidiolex® (cannabidiol) in the ...
GlobeNewswire (press release)
This news release contains forward-looking statements that reflect GW's current expectations regarding future events, including statements regarding financial performance, the timing of clinical trials, the timing and outcomes of regulatory or ...

and more »

Recro Pharma Reports Inducement Grants for New Staff - GlobeNewswire (press release)

December 29, 2017 - 7:00am

Recro Pharma Reports Inducement Grants for New Staff
GlobeNewswire (press release)
... financial goals, including financial guidance; the Company's ability to raise future financing for continued development, product commercialization and the payment of milestones; the Company's ability to pay its debt; customer product performance ...

and more »

GW Pharmaceuticals Submits Marketing Authorisation Application in Europe for Epidiolex® (cannabidiol) in the ... - GlobeNewswire (press release)

December 29, 2017 - 7:00am

GW Pharmaceuticals Submits Marketing Authorisation Application in Europe for Epidiolex® (cannabidiol) in the ...
GlobeNewswire (press release)
This news release contains forward-looking statements that reflect GW's current expectations regarding future events, including statements regarding financial performance, the timing of clinical trials, the timing and outcomes of regulatory or ...

and more »

After Trump criticism, China says no illicit oil sales to North Korea - Reuters

December 29, 2017 - 3:48am

Reuters

After Trump criticism, China says no illicit oil sales to North Korea
Reuters
That doesn't include the theft of intellectual property, O.K., which is another $300 billion,” Trump said, according to a transcript of the interview. “If they're helping me with North Korea, I can look at trade a little bit differently, at least for a ...

and more »

Trump says China's stance on North Korea influences his trade policy - Reuters

December 28, 2017 - 10:14pm

Reuters

Trump says China's stance on North Korea influences his trade policy
Reuters
There will never be a friendly solution to the North Korea problem if this continues to happen!” Trump wrote. In The New York Times interview, Trump explicitly tied his administration's trade policy with China to the country's perceived cooperation in ...

and more »

Workhorse Group to Host Investor and Analyst Meetings at the Consumer Electronics Show (CES) 2018 - GlobeNewswire (press release)

December 28, 2017 - 4:05pm

Workhorse Group to Host Investor and Analyst Meetings at the Consumer Electronics Show (CES) 2018
GlobeNewswire (press release)
Factors that could cause actual results to differ materially include, but are not limited to: our limited operations and need to expand in the near future to fulfill product orders; risks associated with obtaining orders and executing upon such orders ...

and more »

Trump says China's stance on North Korea influences his trade policy - Reuters

December 28, 2017 - 11:39am

Reuters

Trump says China's stance on North Korea influences his trade policy
Reuters
There will never be a friendly solution to the North Korea problem if this continues to happen!” Trump wrote. In The New York Times interview, Trump explicitly tied his administration's trade policy with China to the country's perceived cooperation in ...
After Trump criticism, China says no illicit oil sales to North KoreaCBC.ca

all 1,007 news articles »

Trump says China's stance on North Korea influences his trade policy - Reuters

December 28, 2017 - 11:39am

Reuters

Trump says China's stance on North Korea influences his trade policy
Reuters
There will never be a friendly solution to the North Korea problem if this continues to happen!” Trump wrote. In The New York Times interview, Trump explicitly tied his administration's trade policy with China to the country's perceived cooperation in ...

and more »

Shareholders Turn Down Tender Offer to Take BioCanCell Private ... - GlobeNewswire (press release)

December 28, 2017 - 9:23am

Shareholders Turn Down Tender Offer to Take BioCanCell Private ...
GlobeNewswire (press release)
JERUSALEM, Dec. 28, 2017 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE:BICL), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer, announced today that a full tender ...

and more »

Predictive Technology Group, Inc. (PRED) Announces Issuance of ... - GlobeNewswire (press release)

December 28, 2017 - 9:02am

GlobeNewswire (press release)

Predictive Technology Group, Inc. (PRED) Announces Issuance of ...
GlobeNewswire (press release)
Issuance Strengthens Commercialization Strategy of Company's Gene-Based Endometriosis Diagnostics and Therapeutics.

and more »

Cellular Biomedicine Group Announces Closing of $14.5 Million Private Placement Offering - GlobeNewswire (press release)

December 28, 2017 - 7:30am

Cellular Biomedicine Group Announces Closing of $14.5 Million Private Placement Offering
GlobeNewswire (press release)
... services or development thereof, results of our clinical research and development, regulatory infrastructure governing cell therapy and cellular biopharmaceuticals, our ability to enter into agreements with any necessary manufacturing, marketing ...

and more »

GW Pharmaceuticals Announces Acceptance of NDA Filing for ... - GlobeNewswire (press release)

December 28, 2017 - 7:00am

GW Pharmaceuticals Announces Acceptance of NDA Filing for ...
GlobeNewswire (press release)
LONDON and CARLSBAD, Calif., Dec. 28, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary ...

and more »

ASMI Share Buyback Update December 18-22, 2017 Amsterdam ... - GlobeNewswire (press release)

December 27, 2017 - 11:46am

ASMI Share Buyback Update December 18-22, 2017 Amsterdam ...
GlobeNewswire (press release)
ASM International N.V. (Euronext Amsterdam: ASM) reports the following transactions, conducted under ASMI's current share buyback program. Date, Repurchased shares, Average price, Repurchased value. December 18, 2017, 36,425, € 56.93, € 2,073,624 ...

and more »